{"id":1587,"date":"2020-10-15T09:30:21","date_gmt":"2020-10-15T16:30:21","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=1587"},"modified":"2020-10-16T09:31:20","modified_gmt":"2020-10-16T16:31:20","slug":"safety-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-bbibp-corv-a-randomised-double-blind-placebo-controlled-phase-1-2-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/10\/15\/safety-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-bbibp-corv-a-randomised-double-blind-placebo-controlled-phase-1-2-trial\/","title":{"rendered":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial"},"content":{"rendered":"<ul>\n<li>In a randomized placebo-controlled phase 1\/2 trial of a SARS-CoV-2 vaccine candidate, BBIBP-CorV, 192 healthy adults were randomized to receive vaccine (2, 4, or 8 \u03bcg) or placebo in a 3:1 ratio, stratified by age (18-59 and \u226560) in phase 1. Adverse reactions within the first 7 days of inoculation were reported by 42 (29%) of 144 vaccine recipients; all were mild or moderate. Neutralizing antibody titers were higher at day 42 among 18-59 year-olds than those \u226560, and demonstrated a dose response. In phase 2, 448 were randomized to receive a single 8 \u03bcg injection or two 4 \u03bcg injections. All adverse reactions remained mild or moderate. Neutralizing antibody titers were significantly higher on day 28 among all two-dose 4 \u03bcg schedules than the single 8 \u03bcg dose (p&lt;0.0001).<\/li>\n<\/ul>\n<p>Xia et al. (Oct 15, 2020). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. The Lancet Infectious Diseases. <a href=\"https:\/\/doi.org\/10.1016\/S1473-3099(20)30831-8\">https:\/\/doi.org\/10.1016\/S1473-3099(20)30831-8<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a randomized placebo-controlled phase 1\/2 trial of a SARS-CoV-2 vaccine candidate, BBIBP-CorV, 192 healthy adults were randomized to receive vaccine (2, 4, or 8 \u03bcg) or placebo in a 3:1 ratio, stratified by age (18-59 and \u226560) in phase 1. Adverse reactions within the first 7 days of inoculation were reported by 42 (29%)&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/10\/15\/safety-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-bbibp-corv-a-randomised-double-blind-placebo-controlled-phase-1-2-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-1587","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=1587"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1587\/revisions"}],"predecessor-version":[{"id":1588,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1587\/revisions\/1588"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=1587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=1587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=1587"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=1587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}